Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.57 |
| ▸ | USP30 | Q70CQ3 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.46 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671402 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2500606 | 1.00 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2500609 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| Hydrochloric Acid SCHEMBL2495441 | 0.98 | EPHX1 (0.56) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2026360 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL556321 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL2024838 | 0.90 | EPHX1 (0.55) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL215297 | 0.90 | EPHX1 (0.65) | EPHX1ALDH1A1MAPTNPC1MAPK1 | |
| SCHEMBL2069710 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 | |
| SCHEMBL6758420 | 0.89 | EPHX1 (0.57) | EPHX1USP30ALDH1A1HSD11B1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 368 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106630205-A | Anti-scale inhibitor for treating industrial circulating water | 安徽省蓝天能源环保科技有限公司 | 2017-05-10 | — | — | CN | claimed |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | MISSION THERAPEUTICS LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | LEIDOS BIOMEDICAL RESEARCH, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4370207-B1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES INC (US) | 2025-12-17 | — | — | EP | disclosed |
| EP-4139299-B1 | KRAS G12D PROTEIN INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2025-12-17 | — | — | EP | disclosed |
| US-20250340548-A1 | KRAS G12C INHIBITORS | FRONTIER MEDICINES CORP (US) | 2025-11-06 | — | — | US | disclosed |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | NIDO BIOSCIENCES, INC. (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250289814-A1 | COMPOUNDS AS PARP1 INHIBITIORS | NINGBO NEWBAY TECH DEVELOPMENT CO LTD (CN) | 2025-09-18 | — | — | US | disclosed |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | NNSA | 2025-08-28 | — | — | US | disclosed |
| US-12291539-B2 | KRAS G12C inhibitors | FRONTIER MEDICINES CORPORATION (US) | 2025-05-06 | — | — | US | disclosed |
| US-20060247226-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | HIMMELSBACH FRANK | 2006-11-02 | — | — | US | disclosed |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-09-14 | — | — | US | disclosed |
| WO-2005047293-A1 | MELANIN-CONCENTRATING HORMONE RECEPTOR ANTAGONISTS AND COMPOSITIONS AND METHODS RELATED THERETO | NEUROCRINE BIOSCIENCES, INC. (US) | 2005-05-26 | — | — | WO | disclosed |
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | TORAY FINE CHEMICALS CO., LTD., A CORPORATION OF JAPAN (JP) | 2004-12-02 | — | — | US | disclosed |
| EP-1460061-A1 | PROCESS FOR PRODUCING 1-ALKOXYCARBONYL NITROGENOUS SATURATED HETEROCYCLIC DERIVATIVE | Toray Fine Chemicals Co., Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | LABORATORIOS VITA, S.A. (ES) | 2004-07-29 | — | — | US | disclosed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
| US-6140347-A | Azetidine, pyrrolidine and piperidine derivatives as 5-HT receptor agonists | MERCK SHARP & DOHME LTD. (GB) | 2000-10-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242888-A1 | Process for producing 1-alkoxycarbonyl nitrogenous saturated heterocyclic derivative | DAO, DDO, ODC1 | EPHX1 2315/4885USP30 2643/4885ALDH1A1 2193/4885 |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | EPHX1 919/4885USP30 2578/4885ALDH1A1 187/4885 |
| US-20250270225-A1 | COMPOSITIONS AND METHODS FOR INHIBITION OF RAS | KRAS, NRAS, HRAS | EPHX1 697/4885USP30 1258/4885ALDH1A1 3077/4885 |
| US-20250289814-A1 | COMPOUNDS AS PARP1 INHIBITIORS | PARP1, PARP11, PARP12 | EPHX1 4480/4885USP30 1745/4885ALDH1A1 434/4885 |
| US-20060205711-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | EPHX1 837/4885USP30 2353/4885ALDH1A1 238/4885 |
| US-20060247226-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | EPHX1 837/4885USP30 2353/4885ALDH1A1 238/4885 |
| US-12291539-B2 | KRAS G12C inhibitors | KRAS, NRAS, HRAS | EPHX1 1898/4885USP30 1382/4885ALDH1A1 3319/4885 |
| US-20250340548-A1 | KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | EPHX1 1898/4885USP30 1382/4885ALDH1A1 3319/4885 |
| US-12637426-B2 | 1-cyano-pyrrolidine compounds as USP30 inhibitors | USP30, USP1, USP10 | EPHX1 3856/4885USP30 1/4885ALDH1A1 1185/4885 |
| US-12448368-B2 | Indole compounds as androgen receptor modulators | AR, FSHR, ADRB3 | EPHX1 4776/4885USP30 2794/4885ALDH1A1 2697/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | EPHX1 919/4885USP30 2578/4885ALDH1A1 187/4885 |
| US-12528818-B2 | Compositions and methods for inhibition of RAS | KRAS, NRAS, HRAS | EPHX1 1925/4885USP30 1723/4885ALDH1A1 2644/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | EPHX1 1997/4885USP30 2621/4885ALDH1A1 178/4885 |
| US-20040147545-A1 | Derivatives of oxazolidinones as antibacterial agents | OXA1L, Q6ZSR9, PGC | EPHX1 2356/4885USP30 4108/4885ALDH1A1 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.